The Indian Journal of Pediatrics

, Volume 86, Issue 3, pp 287–295 | Cite as

Dengue and Chikungunya Infections in Children

Guest Editor: Bhim S. Pandhi
  • Nitin Dhochak
  • Sushil K. Kabra
  • Rakesh LodhaEmail author
Review Article


Dengue and Chikungunya are two important mosquito-borne acute febrile illnesses in children. With increased urbanization and newer strains of chikungunya virus with improved transmission with Aedes albopictus, the at-risk population for these infections has greatly increased. Dengue fever has been classified by WHO as dengue with/ without warning signs and severe dengue. Severe dengue is associated with hemorrhagic manifestations, hypovolemia and hypotension secondary to third space loss due to capillary leak or severe end organ dysfunction. NS1 antigen detection and dengue polymerase chain reaction, [polymerase chain reaction (PCR during first 5 d)] and IgM for dengue (6th day of fever onwards) are commonly utilized diagnostic tests. Appropriate fluid therapy with timely tapering of intravenous fluid rate with hematocrit, treatment of hemorrhagic manifestations and clinical monitoring are the mainstay of dengue treatment. Chikungunya has less severe course with shorter febrile phase with prominent and persistent joint symptoms. PCR and IgM against chikungunya are appropriate investigations. Treatment is supportive for chikungunya infection with appropriate joint pain relief.


Dengue Chikungunya Hemorrhagic fever Tropical infections Aedes 



ND contributed in formulating and writing the manuscript. SKK and RL contributed by formulating the plan, supervising and modifying the manuscript. RL will act as guarantor for this paper.

Compliance with Ethical Standards

Conflict of Interest



  1. 1.
    Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the global burden of disease study 2013. Lancet Infect Dis. 2016;16:712–23.CrossRefGoogle Scholar
  2. 2.
    Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): a new public health dilemma in dengue control. Med J Armed Forces India. 2015;71:67–70.CrossRefGoogle Scholar
  3. 3.
    Chan M, Johansson MA. The incubation periods of dengue viruses. PLoS One. 2012;7:e50972.CrossRefGoogle Scholar
  4. 4.
    Sellahewa KH. Pathogenesis of dengue haemorrhagic fever and its impact on case management. ISRN Infect Dis. 2013; Article ID: 571646, 6 pages.
  5. 5.
    Verhagen LM, de Groot R. Dengue in children. J Infect. 2014;69:S77–86.CrossRefGoogle Scholar
  6. 6.
    Kabra SK, Juneja R, Madhulika, et al. Myocardial dysfunction in children with dengue haemorrhagic fever. Natl Med J India. 1998;11:59–61.Google Scholar
  7. 7.
    Pothapregada S, Kamalakannan B, Thulasingam M. Role of platelet transfusion in children with bleeding in dengue fever. J Vector Borne Dis. 2015;52:304–8.Google Scholar
  8. 8.
    Pothapregada S, Kamalakannan B, Thulasingham M, Sampath S. Clinically profiling pediatric patients with dengue. J Global Infect Dis. 2016;8:115–20.CrossRefGoogle Scholar
  9. 9.
    Pothapregada S, Kamalakannan B, Thulasingam M. Clinical profile of atypical manifestations of dengue fever. Indian J Pediatr. 2016;83:493–9.CrossRefGoogle Scholar
  10. 10.
    Dengue: Guidelines for diagnosis, treatment, prevention and control: new edition. Geneva: World Health Organization; 2009. Available at: Accessed 13 May 2018.
  11. 11.
    Tricou V, Vu HTT, Quynh NVN, et al. Comparison of two dengue NS1 rapid tests for sensitivity, specificity and relationship to viraemia and antibody responses. BMC Infect Dis. 2010;10:142.CrossRefGoogle Scholar
  12. 12.
    Teoh B-T, Sam S-S, Tan K-K, et al. The use of NS1 rapid diagnostic test and qRT-PCR to complement IgM ELISA for improved dengue diagnosis from single specimen. Sci Rep. 2016;6:27663.CrossRefGoogle Scholar
  13. 13.
    Hunsperger EA, Yoksan S, Buchy P, et al. Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody. PLoS Negl Trop Dis. 2014;8:e3171.CrossRefGoogle Scholar
  14. 14.
    Handbook for Clinical Management of Dengue. World Health Organization & UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; 2012. Available at: Accessed 13 May 2018.
  15. 15.
    Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005;353:877–89.CrossRefGoogle Scholar
  16. 16.
    Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis. 2001;32:204–13.CrossRefGoogle Scholar
  17. 17.
    Dung NM, Day NP, Tam DT, et al. Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis. 1999;29:787–94.CrossRefGoogle Scholar
  18. 18.
    Lye DC, Archuleta S, Syed-Omar SF, et al. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. Lancet. 2017;389:1611–8.CrossRefGoogle Scholar
  19. 19.
    Kabra SK, Jain Y, Kabra M, et al. Role of platelet transfusion in dengue hemorrhagic fever. Indian Pediatr. 1998;35:452–5.Google Scholar
  20. 20.
    Ewalenko P, Deloof T, Peeters J. Composition of fresh frozen plasma. Crit Care Med. 1986;14:145–6.CrossRefGoogle Scholar
  21. 21.
    Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet. 2000;355:1053–9.CrossRefGoogle Scholar
  22. 22.
    Gala HC, Avasthi BS, Lokeshwar MR. Dengue shock syndrome with two atypical complications. Indian J Pediatr. 2012;79:386–8.CrossRefGoogle Scholar
  23. 23.
    Henter J-I, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefGoogle Scholar
  24. 24.
    Tan LH, Lum LCS, Omar SFS, Kan FK. Hemophagocytosis in dengue: comprehensive report of six cases. J Clin Virol. 2012;55:79–82.CrossRefGoogle Scholar
  25. 25.
    WHO. Revised SAGE recommendation on use of dengue vaccine. Available at: Accessed 23 May 2018.
  26. 26.
    Moi ML, Takasaki T, Kurane I. Human antibody response to dengue virus: implications for dengue vaccine design. Trop Med Health. 2016;44:1.CrossRefGoogle Scholar
  27. 27.
    Petersen LR, Powers AM. Chikungunya: epidemiology. F1000Res. 2016;5:84.Google Scholar
  28. 28.
    Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis. 2009;49:942–8.CrossRefGoogle Scholar
  29. 29.
    NVBDCP. National Vector Borne Disease Control Programme. Available at: Accessed 30 May 2018.
  30. 30.
    Manore CA, Hickmann KS, Xu S, Wearing HJ, Hyman JM. Comparing dengue and chikungunya emergence and endemic transmission in A. aegypti and A. albopictus. J Theor Biol. 2014;356:174–91.CrossRefGoogle Scholar
  31. 31.
    Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol. 2010;8:491–500.CrossRefGoogle Scholar
  32. 32.
    Guidelines on Clinical Management of Chikungunya Fever. Available at: Accessed 30 May 2018.
  33. 33.
    Simon F, Javelle E, Cabie A, et al. French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Méd Mal Infect. 2015;45:243–63.CrossRefGoogle Scholar
  34. 34.
    Goupil BA, Mores CN. A review of chikungunya virus-induced arthralgia: clinical manifestations, therapeutics, and pathogenesis. Open Rheumatol J. 2016;10:129–40.Google Scholar
  35. 35.
    Torres JR, Falleiros-Arlant LH, Dueñas L, Pleitez-Navarrete J, Salgado DM, Castillo JB-D. Congenital and perinatal complications of chikungunya fever: a Latin American experience. Int J Infect Dis. 2016;51:85–8.CrossRefGoogle Scholar
  36. 36.
    Sá PK de O, Nunes de MM, Leite IR, et al. Chikungunya virus infection with severe neurologic manifestations: report of four fatal cases. Rev Soc Bras Med Trop. 2017;50:265–8.CrossRefGoogle Scholar
  37. 37.
    Singh A, Jain R. Neurological manifestations of chikungunya in children. Indian Pediatr. 2017;54:249.CrossRefGoogle Scholar
  38. 38.
    Lewthwaite P, Vasanthapuram R, Osborne JC, et al. Chikungunya virus and central nervous system infections in children, India. Emerg Infect Dis. 2009;15:329–31.CrossRefGoogle Scholar
  39. 39.
    Crosby L, Perreau C, Madeux B, et al. Severe manifestations of chikungunya virus in critically ill patients during the 2013–2014 Caribbean outbreak. Int J Infect Dis. 2016;48:78–80.CrossRefGoogle Scholar
  40. 40.
    Johnson BW, Russell BJ, Goodman CH. Laboratory diagnosis of chikungunya virus infections and commercial sources for diagnostic assays. J Infect Dis. 2016;214:S471–4.CrossRefGoogle Scholar
  41. 41.
    Patel P, Abd El Wahed A, Faye O, et al. A field-deployable reverse transcription recombinase polymerase amplification assay for rapid detection of the chikungunya virus. PLoS Negl Trop Dis. 2016;10:e0004953.CrossRefGoogle Scholar
  42. 42.
    Krutikov M, Manson J. Chikungunya virus infection: an update on joint manifestations and management. Rambam Maimonides Med J. 2016;7:e0033. Scholar
  43. 43.
    Tharmarajah K, Mahalingam S, Zaid A. Chikungunya: vaccines and therapeutics. F1000Res. 2017;6:2114.CrossRefGoogle Scholar
  44. 44.
    Zaidi MB, Garcia-Cordero J, Rivero-Gomez R, et al. Competitive suppression of dengue virus replication occurs in chikungunya and dengue co-infected Mexican infants. Parasit Vectors. 2018;11:378.CrossRefGoogle Scholar
  45. 45.
    Mukherjee S, Dutta SK, Sengupta S, Tripathi A. Evidence of dengue and chikungunya virus co-infection and circulation of multiple dengue serotypes in a recent Indian outbreak. Eur J Clin Microbiol Infect Dis. 2017;36:2273–9.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2018

Authors and Affiliations

  1. 1.Department of PediatricsAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations